• Release your full potential

    Be free to be active. Pioneering new territory to set new standards

ABOUT US

MC2 Therapeutics is a mature biotech company pioneering novel treatment paradigms within immunology and inflammation (“I&I”). Read more about MC2 Therapeutics.

Platform

Our two first-in-class and novel mode of action drug candidates are excellent pipeline generators as they both have potential applications in multiple major underserved indications (“I&I pipeline in a product”). We carefully select indications based on science, clinical unmet need and market access considerations. Read more about our platform.

Pipeline

Based on our two first-in-class and novel mode of action drug candidates, we are currently pursuing indications where there are none or very limited approved treatment options. These indications include oral MC2-32 for Hidradenitis Suppurativa (Ph2a completed) and MC2-25 for Chronic Kidney Disease-associated Pruritus (Ph2 enrollment completed, n=111) and MC2-25 for Vulvar Lichen Sclerosus (Ph2a ongoing). Read more about our pipeline.

LATEST NEWS

mc2_news-image-icon-07

MC2 Therapeutics to Present at Upcoming Conferences

Copenhagen, February 26th, 2024 – MC2 Therapeutics, a commercial stage biotech company focused on developing ...

READ FULL ARTICLE

mc2_news-image-icon-07

MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial

  • MC2-25 CKD is a first-in-class drug candidate and a potential breakthrough in the understanding and ...

    READ FULL ARTICLE

 

mc2_news-image-icon-05

MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus

  • MC2-25 VLS is a first-in-class drug candidate for urea associated skin diseases using a di-peptide ...

    READ FULL ARTICLE

mc2_news-image-icon-07

MC2 Therapeutics Announces Positive Phase 2a Results of Novel HSP90 Inhibitor for Hidradenitis Suppurativa Presented at EADV

  • MC2-32 (RGRN-305) a first in class, oral therapy targeting multiple pathways involved in Hidradenitis Suppurativa ...

    READ FULL ARTICLE